Running mate for a healthier tomorrow in Korea

The Korea Health Industry Development Institute (KHIDI) is a government-affiliated organization, under the Ministry of Health and Welfare of Korea. KHIDI carries out national affairs on the goals of fostering the domestic health industry, strengthening its international competitiveness, and consequently improving people’s quality of life in order to contribute to the advancement of Korea as a global bio and digital health hub.

A consensus on the importance of the health industry has formed to build a safe and healthy society against the health risks derived from emerging infectious diseases and a super-aged society. To foster the health industry for the healthy future of our families and neighbours — this is the role and calling of KHIDI.

KHIDI supports for Korea biopharma globalization
In line with the industry’s increased globalization move, KHIDI support the domestic biopharma industry through various ways from consulting services to networking opportunities with global key stakeholders.

The on-site/online consulting with global pharmaceutical experts
KHIDI provides consulting services to help enter the global market with Global Pharmaceutical Key Opinion Leaders (GPKOLs) and global pharmaceutical experts. It provides customized information on drug development sectors such as R&D, clinical trials, regulatory affairs (RA), business development (BD), project management (PM), and Good Manufactuing Practices (GMP). In doing so, KHIDI supports companies to build innovative new drug development strategies and access global markets.

Support global collaboration for open innovation
KHIDI strives to provide a variety of opportunities to collaborate with global pharmaceutical companies, including pitching, partnering, and more. We invite various global pharmaceutical companies to share the latest trends and status of global open innovation with Korean companies and provide the latest information, such as collaboration strategies, at the Global Open Innovation Week event. In addition, we support participation in major overseas exhibitions for further collaborations in global markets.

Support global market entry for promising Korean biopharma companies
As of September 2024, KHIDI provides 30 Korean companies work spaces at the Cambridge Innovation Center (CIC) in the Boston biocluster in the U.S. It not only provides office space at the CIC, but also supports networking for entry into the U.S. market. It is also enabling consultations with U.S. experts on setting up companies, progressing clinical trials and regulatory reviews and approvals, as well as out-licensing deals.

• For more information, visit: https://www.khidi.or.kr/eps